OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors
Victor Yang, Tue Wenzel Kragstrup, Christopher McMaster, et al.
Drug Safety (2023) Vol. 46, Iss. 11, pp. 1049-1071
Open Access | Times Cited: 27
Victor Yang, Tue Wenzel Kragstrup, Christopher McMaster, et al.
Drug Safety (2023) Vol. 46, Iss. 11, pp. 1049-1071
Open Access | Times Cited: 27
Showing 1-25 of 27 citing articles:
Safety of Janus kinase inhibitors in rheumatoid arthritis: a disproportionality analysis using FAERS database from 2012 to 2022
Bahar Mikaeili, Zuhair Alqahtani, Ana L. Hincapie, et al.
Clinical Rheumatology (2025)
Open Access | Times Cited: 1
Bahar Mikaeili, Zuhair Alqahtani, Ana L. Hincapie, et al.
Clinical Rheumatology (2025)
Open Access | Times Cited: 1
Comparative Effectiveness of Upadacitinib and Tofacitinib in Ulcerative Colitis: A US Propensity-Matched Cohort Study
Gursimran Kochhar, Himsikhar Khataniar, Vipul Jairath, et al.
The American Journal of Gastroenterology (2024)
Closed Access | Times Cited: 8
Gursimran Kochhar, Himsikhar Khataniar, Vipul Jairath, et al.
The American Journal of Gastroenterology (2024)
Closed Access | Times Cited: 8
Cancer Risk in IBD Patients Treated with JAK Inhibitors: Reassuring Evidence from Trials and Real-World Data
Pierluigi Puca, Angelo Del Gaudio, Jacopo Iaccarino, et al.
Cancers (2025) Vol. 17, Iss. 5, pp. 735-735
Open Access
Pierluigi Puca, Angelo Del Gaudio, Jacopo Iaccarino, et al.
Cancers (2025) Vol. 17, Iss. 5, pp. 735-735
Open Access
Serum Lipids Alterations in Patients Under Systemic JAK Inhibitors Treatments in Dermatology: Clinical Aspects and Management
Giovanni Paolino, Mario Valenti, Andrea Carugno, et al.
Medicina (2025) Vol. 61, Iss. 1, pp. 54-54
Open Access
Giovanni Paolino, Mario Valenti, Andrea Carugno, et al.
Medicina (2025) Vol. 61, Iss. 1, pp. 54-54
Open Access
3,6-Anhydro-L-galactose suppresses mouse lymphocyte proliferation by attenuating JAK-STAT growth factor signal transduction and G1-S cell cycle progression
Shin Young Park, Ki Yun Kim, Won Young Jang, et al.
International Immunopharmacology (2025) Vol. 147, pp. 113998-113998
Open Access
Shin Young Park, Ki Yun Kim, Won Young Jang, et al.
International Immunopharmacology (2025) Vol. 147, pp. 113998-113998
Open Access
Patient-Centric Approach for the Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease in Older People
Kevin T Mueller, Alene A Saavedra, Lauren A. O’Keeffe, et al.
Drugs & Aging (2025)
Closed Access
Kevin T Mueller, Alene A Saavedra, Lauren A. O’Keeffe, et al.
Drugs & Aging (2025)
Closed Access
Cardiovascular, cancer, and infection risks of Janus kinase inhibitors in rheumatoid arthritis and ulcerative colitis: A nationwide cohort study
Yongtai Cho, Dongwon Yoon, Farzin Khosrow‐Khavar, et al.
Journal of Internal Medicine (2025)
Open Access
Yongtai Cho, Dongwon Yoon, Farzin Khosrow‐Khavar, et al.
Journal of Internal Medicine (2025)
Open Access
Investigating associations between JAK inhibition and venous thromboembolism by systematic mining of large-scale datasets
Stine Rabech Haysen, Ane Langkilde-Lauesen Nielsen, Per Qvist, et al.
Inflammopharmacology (2025)
Open Access
Stine Rabech Haysen, Ane Langkilde-Lauesen Nielsen, Per Qvist, et al.
Inflammopharmacology (2025)
Open Access
Clinician and patient views on janus kinase inhibitors in the treatment of inflammatory arthritis: a mixed methods study
Savia de Souza, Ruth Williams, Elena Nikiphorou
BMC Rheumatology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 3
Savia de Souza, Ruth Williams, Elena Nikiphorou
BMC Rheumatology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 3
Review: Risk Stratification of Patients With Ulcerative Colitis for Treatment With Tofacitinib
Silvio Danese, Julián Panés, Marla Dubinsky, et al.
Crohn s & Colitis 360 (2024) Vol. 6, Iss. 4
Open Access | Times Cited: 3
Silvio Danese, Julián Panés, Marla Dubinsky, et al.
Crohn s & Colitis 360 (2024) Vol. 6, Iss. 4
Open Access | Times Cited: 3
JAK inhibitors and black box warnings: what is the future for JAK inhibitors?
Yekaterina Tokareva, Pankti Reid, Victor Yang, et al.
Expert Review of Clinical Immunology (2023) Vol. 19, Iss. 11, pp. 1385-1397
Open Access | Times Cited: 8
Yekaterina Tokareva, Pankti Reid, Victor Yang, et al.
Expert Review of Clinical Immunology (2023) Vol. 19, Iss. 11, pp. 1385-1397
Open Access | Times Cited: 8
Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study
Virginia Solitano, Paola Facheris, Magnus Petersen, et al.
Autoimmunity Reviews (2023) Vol. 23, Iss. 3, pp. 103504-103504
Open Access | Times Cited: 7
Virginia Solitano, Paola Facheris, Magnus Petersen, et al.
Autoimmunity Reviews (2023) Vol. 23, Iss. 3, pp. 103504-103504
Open Access | Times Cited: 7
Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis
April W. Armstrong, Melinda Gooderham, Charles Lynde, et al.
JAMA Dermatology (2024) Vol. 160, Iss. 10, pp. 1066-1066
Open Access | Times Cited: 2
April W. Armstrong, Melinda Gooderham, Charles Lynde, et al.
JAMA Dermatology (2024) Vol. 160, Iss. 10, pp. 1066-1066
Open Access | Times Cited: 2
JAK inhibitors to treat STAT3 gain-of-function: a single-center report and literature review
Faranaz Atschekzei, Stephan Traidl, Julia Carlens, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Faranaz Atschekzei, Stephan Traidl, Julia Carlens, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
A Systematic Overview of Contraindications and Special Warnings for Biologic and Targeted Synthetic Disease Modifying Antirheumatic Drugs: Establishing a Framework to Create a “Safety Checklist”
Lykke Skaarup, Elvina Ingrid, Alexandre Sepriano, et al.
Drug Safety (2024) Vol. 47, Iss. 11, pp. 1075-1093
Closed Access | Times Cited: 1
Lykke Skaarup, Elvina Ingrid, Alexandre Sepriano, et al.
Drug Safety (2024) Vol. 47, Iss. 11, pp. 1075-1093
Closed Access | Times Cited: 1
Does Concomitant Use of Methotrexate with JAK Inhibition Confer Benefit for Cardiovascular Outcomes? A Commentary
Peter C. Taylor, Alejandro Balsa, Anne‐Barbara Mongey, et al.
Rheumatology and Therapy (2024) Vol. 11, Iss. 6, pp. 1425-1435
Open Access | Times Cited: 1
Peter C. Taylor, Alejandro Balsa, Anne‐Barbara Mongey, et al.
Rheumatology and Therapy (2024) Vol. 11, Iss. 6, pp. 1425-1435
Open Access | Times Cited: 1
Upadacitinib in end stage renal disease: A case of acute severe ulcerative colitis
Patrick Hilley, Danny Con, Matthew C. Choy, et al.
JGH Open (2023) Vol. 7, Iss. 12, pp. 1012-1015
Open Access | Times Cited: 3
Patrick Hilley, Danny Con, Matthew C. Choy, et al.
JGH Open (2023) Vol. 7, Iss. 12, pp. 1012-1015
Open Access | Times Cited: 3
Changes in Characteristics of Patients Initiating and Discontinuing Advanced Therapies for Rheumatoid Arthritis Following the Release of Safety Data
Stephanie Song, Bryant R. England, Brian C. Sauer, et al.
Arthritis Care & Research (2023) Vol. 76, Iss. 4, pp. 463-469
Closed Access | Times Cited: 2
Stephanie Song, Bryant R. England, Brian C. Sauer, et al.
Arthritis Care & Research (2023) Vol. 76, Iss. 4, pp. 463-469
Closed Access | Times Cited: 2
Prevalence of Cardiovascular and Cancer Risk Factors Among Rheumatoid Arthritis Patients Prescribed Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors: A Cross‐Sectional Study
Jud C. Janak, Ryan D. Ross, Brenna L. Brady, et al.
Arthritis Care & Research (2024) Vol. 76, Iss. 9, pp. 1287-1293
Open Access
Jud C. Janak, Ryan D. Ross, Brenna L. Brady, et al.
Arthritis Care & Research (2024) Vol. 76, Iss. 9, pp. 1287-1293
Open Access
Post-marketing safety concerns with abrocitinib: a real-world pharmacovigilance analysis of the FDA adverse event reporting system
Zhu Zhou, Mingjuan Liu, Hanlin Zhang, et al.
Expert Opinion on Drug Safety (2024), pp. 1-8
Closed Access
Zhu Zhou, Mingjuan Liu, Hanlin Zhang, et al.
Expert Opinion on Drug Safety (2024), pp. 1-8
Closed Access
Survey of Potential Drug Interactions, Use of Non-Medical Health Products, and Immunization Status among Patients Receiving Targeted Therapies
Réka Rajj, N Schaadt, Katalin Bezsila, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 7, pp. 942-942
Open Access
Réka Rajj, N Schaadt, Katalin Bezsila, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 7, pp. 942-942
Open Access
Evaluating the Usage of Janus Kinase Inhibitors in Rheumatology and Its Impact on Cardiovascular Risk
Knkush Hakobyan, Talar Acob, Mesrop Aleksanyan, et al.
Cureus (2024)
Open Access
Knkush Hakobyan, Talar Acob, Mesrop Aleksanyan, et al.
Cureus (2024)
Open Access
Screening and Management of Atherosclerotic Cardiovascular Disease in Inflammatory Arthritis: A Comprehensive Approach for the Rheumatologist
Shadi Akhtari, Bindee Kuriya
Canadian rheumatology today. (2024)
Closed Access
Shadi Akhtari, Bindee Kuriya
Canadian rheumatology today. (2024)
Closed Access
An evaluation of mirikizumab for the treatment of ulcerative colitis
Christopher J. White, Peter M. Irving
Expert Opinion on Biological Therapy (2024)
Closed Access
Christopher J. White, Peter M. Irving
Expert Opinion on Biological Therapy (2024)
Closed Access
Interlinking pathways: a narrative review on the role of IL-6 in cancer and atherosclerosis
Riccardo Cau, Luca Saba
Cardiovascular Diagnosis and Therapy (2024) Vol. 14, Iss. 6, pp. 1186-1201
Open Access
Riccardo Cau, Luca Saba
Cardiovascular Diagnosis and Therapy (2024) Vol. 14, Iss. 6, pp. 1186-1201
Open Access
